JP2005506369A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506369A5
JP2005506369A5 JP2003537629A JP2003537629A JP2005506369A5 JP 2005506369 A5 JP2005506369 A5 JP 2005506369A5 JP 2003537629 A JP2003537629 A JP 2003537629A JP 2003537629 A JP2003537629 A JP 2003537629A JP 2005506369 A5 JP2005506369 A5 JP 2005506369A5
Authority
JP
Japan
Prior art keywords
irbesartan
pharmaceutical composition
hydrochlorothiazide
composition according
diuretics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003537629A
Other languages
English (en)
Japanese (ja)
Other versions
JP4542777B2 (ja
JP2005506369A (ja
Filing date
Publication date
Priority claimed from FR0113936A external-priority patent/FR2831446B1/fr
Application filed filed Critical
Publication of JP2005506369A publication Critical patent/JP2005506369A/ja
Publication of JP2005506369A5 publication Critical patent/JP2005506369A5/ja
Application granted granted Critical
Publication of JP4542777B2 publication Critical patent/JP4542777B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003537629A 2001-10-26 2002-10-09 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用 Expired - Fee Related JP4542777B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (3)

Publication Number Publication Date
JP2005506369A JP2005506369A (ja) 2005-03-03
JP2005506369A5 true JP2005506369A5 (enExample) 2006-01-05
JP4542777B2 JP4542777B2 (ja) 2010-09-15

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003537629A Expired - Fee Related JP4542777B2 (ja) 2001-10-26 2002-10-09 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用

Country Status (24)

Country Link
US (2) US20040242567A1 (enExample)
EP (1) EP1441723B1 (enExample)
JP (1) JP4542777B2 (enExample)
CN (1) CN100418526C (enExample)
AT (1) ATE361071T1 (enExample)
AU (1) AU2002350832B2 (enExample)
BR (1) BR0213479A (enExample)
CA (1) CA2461625C (enExample)
CY (1) CY1106746T1 (enExample)
DE (1) DE60219940T2 (enExample)
DK (1) DK1441723T3 (enExample)
EA (1) EA007952B1 (enExample)
ES (1) ES2286304T3 (enExample)
FR (1) FR2831446B1 (enExample)
HU (1) HUP0401633A3 (enExample)
IL (2) IL161116A0 (enExample)
IS (1) IS2849B (enExample)
MX (1) MXPA04003910A (enExample)
NO (1) NO332313B1 (enExample)
NZ (1) NZ532130A (enExample)
PL (1) PL209263B1 (enExample)
PT (1) PT1441723E (enExample)
WO (1) WO2003035062A1 (enExample)
ZA (1) ZA200402696B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
AU2022244585A1 (en) * 2021-03-23 2023-09-21 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (enExample) * 1990-03-20 1993-03-11 Sanofi Co
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Similar Documents

Publication Publication Date Title
ATE461932T1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
JP2005506369A5 (enExample)
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
BR0313629B1 (pt) composiÇço detergente bifÁsica lÍquida aquosa de limpeza pessoal.
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
DE122012000018I1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a II rezeptors.
WO2002081430A3 (en) Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
JP2005526147A5 (enExample)
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
JP2006517944A5 (enExample)
JP2007524571A5 (enExample)
JP2004520453A5 (enExample)
EP1195166A3 (en) Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension
JP2007191765A5 (enExample)
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
JP2007510403A5 (enExample)
WO2007075964A3 (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2005000231A3 (en) Il-8 receptor antagonists
JP2004534810A5 (enExample)
JP2008534513A5 (enExample)
WO2001072960A3 (en) Il-8 receptor antagonists
ECSP066306A (es) Modificaciones estables de maleato ácido de tegaserod